Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2NET 1

Conditions

Neuroendocrine Tumors 4Carcinoid Tumor 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1Adenoma, Islet Cell 1Adenocarcinoma 1Acromegaly 1

Interventions

Everolimus 3pasireotide 2veliparib 1gallium Ga 68 dotatate 1Temozolomide 1Sorafenib 1Rose Bengal 1Radiotherapy 1Radiation 1Proton Therapy 1Octreotide 1Ga(III)-DOTATOC 1Dacarbazine 1Capecitabine 1Bortezomib 1Biological Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Carcinoid Tumor × pasireotide × Clear all
NCT00446082 2020-12-21

Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease

Novartis

Phase 1 Completed
85 enrolled
Endocrine

Acromegaly, Carcinoid Tumor

NCT00804336 2016-10-19

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 1 Completed
22 enrolled
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡